Karyopharm Therapeutics Inc. (KPTI) Shares Gap Up to $7.36
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares gapped up before the market opened on Wednesday . The stock had previously closed at $7.34, but opened at $7.36. Karyopharm Therapeutics shares last traded at $7.56, with a volume of 151,512 shares traded.
KPTI has been the subject of a number of recent research reports. Robert W. Baird initiated coverage on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. They set an “outperform” rating and a $16.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Raymond James Financial Inc. began coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price for the company. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $19.50.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Monday, May 9th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.01.
In related news, major shareholder Ltd Chione sold 18,824 shares of the stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent quarter.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.